Human umbilical cord blood (HUCB) provides a source of progenitors for cell therapy. We isolated and characterized an HUCB-derived population of progenitors (HUCBNP), differentiated toward neuronal phenotype by human neuroblastomaconditioning medium (CM) and nerve growth factor (NGF), which have been found to confer neuroprotection toward hypoxia-mediated neuronal injury. This study investigated whether interferon-c (IFN-c) contributes to HUCBNP differentiation. IFN-c was detected in the CM used for the induction of differentiation of HUCBNP and a neutralizing antibody of IFN-c significantly inhibited either IFN-c or CM-induced differentiation. Transcriptome analysis of CM-differentiated HUCBNP, identified 86 genes as highly upregulated, among them 25 were IFN-induced (such as 2 0 ,5 0 -oligoadenylate synthetase 1 and 2, IFN-induced protein and transmembrane proteins, STAT1 (IFNc-receptor signal transducer and activator of transcription) and chemokine C-X-C motif ligand 5). Treatment of HUCBNP with human recombinant IFN-c, inhibited cell proliferation in a dosedependent manner. IFN-c (1-100 ng/ml) enhanced neuronal differentiation, expressed by neurite outgrowths and increased expression of the neuronal markers b-tubulin III, microtubuleassociated protein 2, neuronal nuclei, neurofilament M and neuronal-specific enolase. IFN-c additively cooperated with NGF to induce the differentiation of HUCBNP. These data indicate that IFN-c promotes neuronal differentiation of HUCBderived progenitors, proposing its use in future protocols towards cell therapy.
Introduction
Human stem cells are viewed as a possible source for cell therapy of neurodegenerative disorders. As the availability of human neuronal stem cells derived from early embryos is extremely limited, progenitors of other origins, such as human umbilical cord blood (HUCB) are being considered. 1 The HUCB contains multiple populations of pluripotent stem cells, such as hematopoietic, 2 epithelial, 3 endothelial, 4 myotubes 5 and neuronal. 6 Thus, HUCB stem cells are well-suited to treat a wide variety of diseases including cardiovascular, ophthalmic, orthopedic, endocrine diseases and neurological disorders. 1 Over the last decade, protocols that generate neurons from HUCB progenitors have been developed. These protocols include non-selective, differentiating chemical agents, such as retinoic acid, dimethylsulfoxide and b-mercaptoethanol, which induced properties typical of neuroectodermal-derived neuronal cells. 7 Our approach was on the basis of isolation of progenitors expressing a1 and a2 collagen-integrin receptors, 6 originally defined as very late antigens 1 and 2FVLA1 and VLA2 or CD49a and CD49b, respectively. 8 These progenitors operationally defined as HUCB-derived neuronal progenitors (HUCBNP) were differentiated by treatment with neuronal-conditioning medium (CM), known to be enriched with growth factors, and inclusion of the typical neurotrophin nerve growth factor (NGF). 6 To elucidate HUCBNP therapeutic potential, they were investigated in a stroke model and were found to confer neuroprotection to the ischemic-insulted neurons by the release of NGF and angiogenic factors. 9 Nevertheless, besides NGF, the other specific growth factor requirement and the cellular mechanisms that underlie the development of HUCBNP in vitro as they are subjected to the specific differentiation protocols are poorly understood. The inability to define the growth factor requirement to stop the proliferation and to induce the differentiation program in vitro represent a major obstacle toward the translation of HUCBNP technology for reparative purposes in neurodegenerative disorders.
Interferon-g (IFN-g) is a cytokine with pleiotropic action characterized by anti-proliferative, anti-viral, 10 immunemodulation 11 and tumor suppression activities. 12 In view of these properties, human recombinant IFN-g (hrIFN-g) was approved by the Food and Drug Administration for adult and pediatric treatment of chronic granulomatous disease and malignant severe osteopetrosis and was considered, with inconclusive evidence, for chronic myeloid leukemia, graft-vshost disease, idiopathic pulmonary fibrosis, ovarian cancer, renal cell carcinoma, rheumatoid arthritis and a variety of infectious diseases. 13 Besides these peripheral effects, IFN-g was also found to play an important role in embryonic neuronal differentiation and neuronal survival. 12 For example, IFN-g facilitates NGF-induced neuronal differentiation, 14 synergistically induced with TNFa neurite outgrowths on PC12 cells neuronal model 15 and promotes cholinergic differentiation of cortical and hippocampal neurons. 16 IFN-g also promotes neuronal differentiation of neural stem cells derived from subventricular zone of adult mice brains 17 and enhances neurogenesis in the dentate gyrus of adult mice and improves the spatial learning and memory performance. 18 In view of the above neurological properties of IFN-g, we address in this study the possibility that the neuronal CM employed by us to induce HUCBNP differentiation 6 may contain IFN-g as a constituent of the growth factors responsible for neuronal differentiation.
Indeed, we proved the existence of IFN-g in the CM, showed an increased expression of typical IFN-related genes in HUCBNP treated with CM and found that IFN-g-induced inhibition of proliferation and promotion of differentiation expressed by neurite outgrowths and induction of typical neuronal markers. These findings propose IFN-g as important neuronal differentiating factor in the future clinical relevant protocols for cell therapy using HUCBNP.
Materials and methods

Separation of HUCBNP
Human umbilical cord blood was collected with the written approval of the mothers, according to a protocol approved by Sheba Medical Center's Committee on Ethics of Human Investigation. Fresh placental blood was stored in ethylenediaminetetraacetic acid-containing bags immediately after delivery, and used within 8 h. The mean gestational age of the donor was 39 þ 2 weeks, and the net volume of each individual cord blood donation was 75 þ 25 ml. The mononuclear cells were isolated twice on a sterile Ficol/Hypaque gradient (IsoPrep; Robbins Scientific Corporation, Sunnyvale, CA, USA), generating a mean count of 1.4 Â 10 8 cells. HUCBNP were isolated and cultured as described earlier. 6, 8 Briefly, mononuclear cells were seeded at a density of approximately 1.8 Â 10 5 /cm 2 on 24-well plates coated with 200 mg/ml type-I rat collagen (BD Biosciences, Bedford, MA, USA) and grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine and antibiotics (100 mg/ml streptomycin and 10 000 U/ml penicillin), all purchased from Biological Industries (Beit Haemek, Afula, Israel). After 7 days, the medium was replaced every 4 days for a total period of 14 days. The cells were grown at 37 1C, at high humidity, 5% CO 2 , in a CO 2 incubator. All experiments were carried out in a clean room, according to ISO7 requirements (10 000 particles/m 2 ).
Production of SH-SY5Y human neuroblastoma-conditioning media (CM)
Proliferating cultures of SH-SY5Y neuroblastoma cells (ATTC, Manassas, VA, USA) were grown in 175 cm 2 tissue culture flasks in a 30 ml volume of DMEM, supplemented with 12% FCS and antibiotics (100 mg/ml streptomycin and 10 000 U/ml penicillin). Freshly prepared, SH-SY5Y CM, collected from cultures at 80-100% confluency, centrifuged twice for 5 min at 8000 r.p.m. and filtered through 0.2 mm millipore filters (Billerica, MA, USA), was added to the HUCB progenitors; 100% CM was defined as 1 ml media collected from 1 Â 10 6 SH-SY5Y-proliferating cells as described earlier. 6, 9 Measurements of cell proliferation and neuronal differentiation Cell proliferation was assessed using the Alamar Blue method, according to the manufacturer's (Invitrogen, Carlsbad, CA, USA) instructions and was calculated by the percentage of fluorescent cells on treatment with 10-1000 ng/ml hrIFN-g in DMEM supplemented with 10% FCS, 2 mM L-glutamine and antibiotics (100 mg/ml streptomycin and 10 000 U/ml penicillin) (hrIFN-g, Sigma, St Louise, MO, USA) compared with untreated cells in the same medium.
To initiate neuronal differentiation, the HUCBNP were treated for up to 14 days with DMEM supplemented with 10% FCS, 2 mM L-glutamine and antibiotics (100 mg/ml streptomycin and 10 000 U/ml penicillin), supplemented with 10% SH-SY5Y (ATTC) neuroblastoma-CM and 10 ng/ml mouse b-subunit, NGF (2S-NGF) (differentiation medium) (Alomone Labs, Jerusalem, Israel). 6, 9 Undifferentiated media (control media) consisted of DMEM supplemented with 10% FCS, 2 mM L-glutamine and antibiotics (100 mg/ml streptomycin and 10 000 U/ml penicillin). 6, 9 To verify the IFN-g effect, 1-1000 ng/ml of hrIFN-g was added either to differentiation medium (to verify the cooperativity with NGF), or to undifferentiating medium (to measure its differentiating inducing properties). Neurite outgrowth length was quantitated in the absence or presence of anti-human IFN-g specific antibody purified by affinity chromatography using human IFN-g immobilized to a matrix (PeproTech, Princeton, NJ, USA). To assess neuronal differentiation, neurite outgrowth length was quantitated using the SigmaScanPro 5.0 program (Systat, Chicago, IL, USA) as previously described by us. 19 Briefly, the total length of outgrowths from each cell in the region of interest was divided by its diameter, thus generating an elongation factor, denoted as elongation (E, n ¼ 3 experiments in triplicates, 30-40 cells in each region of interest) parameter.
Immunocytochemistry
HUCB-derived neuronal progenitors were plated on collagencoated glass chamber slides (Nunc, Roskilde, Denmark) at a seeding density of 1.8 Â 10 5 /cm 2 . After 14 days in vitro, hrIFN-g (100 ng/ml)-treated or control untreated cells were fixed with 4% paraformaldehyde and permeabilized with 0.2% TritonX100 (BDH Chemicals Ltd, Poole, England) for 2 min. They were then washed thrice with phosphate-buffered solution, blocked with 0.5% bovine serum albumin for 1 h at 37 1C and incubated overnight at 4 1C with antibodies directed toward typical neuronal markers as described earlier. 6 In the negative control experiments, the primary antibody was omitted. The number of stained cells was determined using a fluorescence microscope (Axiovert 200, Zeiss, Gö ttingen, Germany). Photographs were acquired with a SensiCam digital camera (PCD, CCD Imaging, Kelhein, Germany) and processed with Image-Pro Plus 6.0 (Media Cybernetics, Silver Spring, MD, USA). The percentage of positively stained cells was calculated from a random series of photographs from different batches of cells by counting the number of fluorescent-positive cells out of the total number of cells in the field on subtracting the fluorescence of hrIFN-gtreated cultures stained with secondary antibody alone, which was non-significant (n ¼ 3 experiments in triplicates, 30 cells in each field).
RT-PCR
Total RNA was isolated and genomic DNA was degraded from the RNA preparations, using the SV total RNA Isolation System (Qiagen GmbH, Hilden, Germany). A quantity of 1 mg of total RNA was reverse transcribed using the Reverse Transcription System (Promega, Madison, WI, USA), according to the manufacturer's instructions. PCR was then carried out as described earlier. 6 For uniformity of comparison, all PCR experiments were conducted for 35 cycles, as these conditions were within the range of linearity as predetermined from several trials. For generation of various complementary DNA fragments, a Mastercycler gradient (Eppendorf, Hamburg, Germany) was programmed as follows: denaturation of cyclic parameters at 94 1C for 1 min, annealing at 65 1C for 1 min and elongation at 72 1C for 2 min. To identify the various neuronal markers, primers were used as reported earlier. 6 For neurofilament-M (430 bp), the sense GAGCGCAAAGACTACCTGAAGA-3 0 and antisense CAGCGATTTCTATATCCAGAGCC-3 0 primers were used. All the reverse transcriptase (RT)-PCR experiments were routinely controlled by conducting PCR without first carrying out a reverse transcription reaction. PCR products were analyzed by electrophoresis on agarose gel (2%) containing ethidium bromide for UV visualization and sequenced to prove identity. SH-SY5Y human neuroblastoma-derived mRNAs served as a positive control for validation. The mRNA levels were semi-quantitatively evaluated by densitometric analysis of the RT-PCR products, carried out using Quantity One 1-D Analysis Software program, 2003 version (Bio-Rad, Hercules, CA, USA). The mean ± s.d. values of the ratio of mRNA growth factor band intensity (arbitrary units) divided by mRNA b-actin of the same experiment were calculated from three independent experiments.
IFN-g ELISA assay
Samples of SH-SY5Y media were collected and assayed for IFN-g levels using the Human IFN-g ELISA Development Kit according to the manufacturer's instructions (PeproTech Inc., Rocky Hill, NJ, USA). The amount of IFN-g in pg/ml was calculated from the IFN-g standard curve, within the range of 32-2000 pg/ml by measuring the differences in absorbance subtracting the optical density at 650 nm from the optical density at 405 nm, according to the manufacturer's instructions. The experiments were repeated five times at different medium dilutions.
Western blot
SH-SY5Y CM was collected from 80-100% confluent proliferating cultures of SH-SY5Y neuroblastoma cells, grown in 175 cm 2 tissue culture flasks in a 30 ml volume of DMEM, supplemented with 0.1% FCS and antibiotics (100 mg/ml streptomycin and 10 000 U/ml penicillin). CM was centrifuged twice for 5 min at 8000 r.p.m., filtered through 0.2 mm millipore filters, dialyzed overnight at 4 1C using pre-heated dialysis bags (cutoff 1000) and lyophilized. Protein extracts from neuroblastoma cells or CM preparations were isolated using a lysis buffer solution (Clontech, Mountain View, CA, USA). The amount of total protein extracted was determined by the BIO-RAD Protein assay (Bio-Rad). Protein samples of 10-20 mg were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The proteins were electrotransferred (100 V, 1.5 h, 4 1C) to nitrocellulose membranes and incubated for 2 h at room temperature with 5% non-fat powdered milk in Tris-buffered saline containing 0.1% Tween 20. Immunodetection was carried out overnight at 4 1C using anti-human IFN-g polyclonal antibody (1:1000; PeproTech Inc.). The membranes were then washed and probed with secondary antibody: horseradish-peroxidaseconjugated goat anti-rabbit (1:10 000, Jackson Immuno Research, West Grove, PA, USA) for 1 h at room temperature, and developed using the ECL reagent (Pierce, Rockford, IL, USA), allowing visualization of the proteins.
RNA preparation, labeling, hybridization, data collection and analysis for GeneChip experiment HUCB-derived neuronal progenitors were isolated from fullterm HUCB blood units from three donors and processed separately, either as undifferentiated (left untreated) or differentiated (CM-treated for 7 days), to generate six different microarray analyses. Therefore, these analyses enable estimation of the gene expression variability of HUCBNP derived from different donors. HUCBNP from each blood sample were treated for 7 days with CM or left untreated. Total RNA from each individual sample was then purified according to the manufacturer's technical protocol (Affymetrix, Santa Clara, CA, USA), selected on the basis of RNA quality (ratio of 41.90 at A260/A280 nm and integrity evaluated by 1.2% agarose electrophoresis) and used to prepare biotinylated target RNA. RNA was used to generate first-strand complementary DNA by using a T7-linked oligo(dT) primer. After second-strand synthesis, in vitro transcription was carried out with biotinylated UTP and CTP (Enzo Diagnostics, New York, NY, USA), resulting in approximately 100-fold amplification of RNA. Target complementary DNA generated from each sample was then processed using an Affymetrix GeneChip Instrument System (Affymetrix). Arrays were then washed and stained with streptavidin phycoerythrin before being scanned on an Affymetrix GeneChip scanner (Affymetrix) using Affymetrix Human Genome U133A oligonucleotide arrays (Affymetrix). This gene chip contains about 45 000 probe sets representing more than 39 000 transcripts derived from approximately 15 000 annotated and predicted human genes and their alternative spliced variants. The signals on each array were normalized according to the routine procedure. The stability of the experiments and the quality of the DNA array were confirmed by using internal standards, as well as by analyzing the internal distribution of the signal in each array. The scatter plots revealed that all the six samples reported had correlation coefficients 40.85. The full list of valid probe sets, representing probe sets with signals 420 and detected as present in all samples, was analyzed for hierarchal clustering using Spotfire Decision Site (Somerville, MA, USA) for functional genomics. The comparison generated a list of 172 total changed probe sets from which 99 were upregulated and 73 were downregulated probe sets. These probe sets were changed by at least twofold, as calculated by the MAS 5 (Microarray Suite 5.0) log ratio value (P-value 0.003) in all CM-treated samples as compared with the control untreated samples. 20, 21 The annotations of HG-U133A chips and MAS5.0 statistical algorithms are available at http:// www.affymetrix.com.
Statistics
The results, unless otherwise stated, are presented as the mean±s.e.m. and evaluated using the GraphPad InStat 3 program (GraphPad Software Inc., San Diego, CA, USA). Statistically significant differences between the experimental groups were determined by ANOVA (analysis of variance) followed by Bonferroni post-test and were considered significant when Po0.01 and differences on gene expression were considered significant when Po0.05.
Results
IFN-g presence in the CM
The presence of IFN-g in the CM was detected by ELISA and western blotting experiments (Figure 1 ). The range of IFN-g concentrations detected in different batches of CM was between 150-370 pg/ml. In western blotting experiments, a single immunoreactive protein with an apparent molecular weight of about 18 kD was detected, whereas in control experiments using hrIFN-g, the apparent molecular weight of the immunoreactive protein was about 22 kD. The apparent shift in the mobility of CM IFN-g compared with hrIFN-g is explained by differences in their glycosylation. 22 To verify that CM-induced HUCBNP neuronal differentiation 6, 9 is mediated by the presence of IFN-g in the CM, a neutralization experiment was performed. HUCBNP were treated for 7 or 14 days with CM in the presence or absence of increasing concentrations of selective anti-IFN-g antibody and the neuronal differentiation of the progenitors was estimated by the degree of elongation (E) of the neurite outgrowths ( Figure 2 ). The data clearly indicate that by increasing the ratio between the antibody and the CM, a gradual significant inhibition of CM-induced HUCBNP differentiation was obtained. At the highest ratio investigated, the maximal inhibition of HUCBNP neuronal differentiation achieved was 47 and 48% at 7 and 14 days of treatment (Po0.01), respectively, suggesting the contribution of IFN-g in the CMinduced differentiation process.
As the pleiotropic activities of IFN-g are mediated primarily through the transcriptional regulation of many downstream effector genes, conveniently measured by oligonucleotide gene arrays, 23 we treated HUCBNP with CM for 7 days and analyzed their gene expression profile compared with control untreated cells using an Affimatrix human microarray (Affimatrix) (Figure 3 and Table 1 ). To identify CM-regulated genes, pair-wise comparisons were generated between the data sets from CM-treated and the untreated cell data sets HUCBNP. Hierarchical clustering analysis showed distinct gene group expression profile for all CM-treated samples as compared with control untreated samples (Figure 3) . Global gene expression analysis indicates that more than 7820 genes were upregulated after CM-stimulation. The majority represented genes for which the degree of change was less than twofold. The number of genes whose expression was upregulated more than twofold was 86. We found that among these genes, about 25 were IFNrelated. The typical hallmark genes induced by IFN-g, 2 0 -5 0 -oligoadenylate synthetase isoforms, IFN-induced proteins and transmembrane proteins, guanylate-binding proteins and STAT1 (IFN-g-receptor signal transducer and activator of transcription) were significantly upregulated by CM in HUCBNP (Table 1) , as also reported on treatment of human fibrosarcoma cells 23 and human umbilical vein endothelial cells 24 with IFN-g. It is interesting that the monokine CXCL5 gene was found to be highly induced, reminiscent of the induction by IFN-g of Mig (CXCL9), which belongs to the same CLC chemokine Interferon-c-induced neuronal differentiation of cord blood progenitors H Arien-Zakay et al sub-family, which acts as a neurotrophic factor inducing neurite outgrowths in sympathetic neurons. 25 Furthermore, CM treatment of HUCBNP induced VEGF gene expression, as also found on IFN-g treatment of endothelial cells. 24 VEGF, besides its wellknown angiogenic properties is characterized by neurotrophic activities and induction of neurite outgrowths in neurons. 26 In conclusion, the IFN-g fingerprint gene expression of HUCBNP on treatment with CM provides a strong additional evidence of the presence and activity of IFN-g in the CM.
Furthermore, global gene expression analysis indicates that 48939 genes were downregulated after CM-stimulation. The majority represented those genes for which the degree of change was otwofold. The number of genes whose expression was downregulated 4twofold was 52. We have found that among these genes, 23 hematopoietic-related genes were downregulated (Table 2) . Typical erythroid lineage genes such as hemoglobin subunits a, b and g, and T-cell lineage including T-cell receptors a and b subunits, lymphocyte-specific protein tyrosine kinase, CD3D and CD3Z antigens, all were significantly downregulated. These findings strongly suggest that in parallel to the neuronal commitment, the HUCBNP express less hematopoietic genes.
Exogenous IFN-g treatment inhibited proliferation of HUCBNP
To confirm IFN-g effects on HUCBNP, we evaluated the cell survival and proliferation effect of hrIFN-g supplemented to the culture growth medium (Figure 4) . Treatment of HUCBNP with 10-1000 ng/ml hrIFN-g for up to 72 h, significantly inhibited (Po0.01) cell proliferation without affecting cell viability, supporting the basic characteristics of IFN-g. 15 ,27 a Gene entries are sorted on the basis of an average Log2 ratio 41 of CM-treated over untreated samples (after filtering for expression in all the three microarray replicates); s.e.m. of three independent experiments using HUCB from three different donors (Figure 3 ). *Po0.05 CM-treated compared with untreated control.
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Exogenous IFN-g treatment promoted neuronal differentiation of HUCBNP As IFN-g inhibited HUCBNP proliferation, we next determined whether IFN-g affects HUCBNP neuronal differentiation as documented earlier for embryonic mouse cerebellum neural progenitors. 28 On 14 days of treatment of HUCBNP with hrIFN-g, the cells undergo hypertrophy, transformed to a bipolar or multipolar or fibroblast-like morphotypes, expressing neurite outgrowths of different lengths (Figures 5a and b) , as reported on treatment of neuroblastoma or PC12 neurons with hrIFN-g, 15, 27 resembling the morphological plasticity of neuronal cultures.
A typical dose-response effect of hrIFN-g on morphological neuronal-like differentiation of the HUCBNP is presented in Figure 5c . On treatment of HUCBNP with 100 ng/ml hrIFN-g for 7 and 14 days, a 3.8-and 7.1-fold longer neurites are formed, respectively, compared with control. The hrIFN-g-induced HUCBNP neuronal differentiation was effectively inhibited on combined treatment of the cells with hrIFN-g and anti-IFN-g specific antibody (Figure 5d ).
To further explore the ability of HUCBNP to differentiate into neuronal-like cells on IFN-g treatment, as reported for earlier CM, 6 we investigated the expression of neuronal markers in Gene entries are sorted on the basis of an average Log2 ratio 41 of CM-treated over untreated samples (after filtering for expression in all three microarray replicates); s.e.m. of three independent experiments using HUCB from three different donors (Figure 3 ). *Po0.05 CM-treated compared with untreated control.
Interferon-c-induced neuronal differentiation of cord blood progenitors H Arien-Zakay et al these cells, evaluated by mRNA expression (Figures 6a and b) , and immunocytochemistry (Figures 6c and d) . Whereas the mRNA level of nestin, a typical neuronal progenitor marker, 29 was decreased by 3.4-fold, the level of the mature neuronal markers microtubule-associated protein 2, neurofilament-M and neuronal specific enolase were increased by 8.6-, 3.4-and 4.4-fold, respectively, compared with control untreated cells (Figure 6b ). The percentage of nestin immunofluorescent cells also decreased by 1.2-fold, whereas the percentage of the mature neuronal markers microtubule-associated protein 2, b-tubulin III and neuronal nuclear protein immunofluorescent cells was increased by 3.9-, 6-, and 10.4-fold, respectively, compared with control untreated cells (Figure 6d ). Thus, hrIFNg-induced morphological differentiation is accompanied by the induction of expression of neuronal markers, supporting the hrIFN-g induced differentiated phenotype of HUCBNP.
IFN-g cooperates with NGF in neuronal differentiation of HUCBNP
As HUCBNP have been induced toward neuronal differentiation by CM and/or NGF 6 and IFN-g was reported to facilitate NGFinduced neuronal differentiation, 14, 30 we investigated the combined effect of hrIFN-g and NGF on HUCBNP (Figure 7) . It is evident that the combined treatment, either at 7 or 14 days, induced a significant higher differentiation response compared with the effect of each individual factor.
Discussion
Development of ex vivo conditions that enable in vitro maintenance and differentiation of transplantable HUCBNP represent a major challenge in stem cell therapy. Establishment of these conditions is a pre-requisite for HUCBNP translational cell therapy for neurodegenerative disorders. The aim of this study was to explore the hypothesis that human neuroblastomaconditioning medium contains IFN-g, and that IFN-g is required for commitment for differentiation of these neuronal progenitors. IFN-g is known to be an anti-proliferative, differentiating agent in many cell types, including neuroblastoma and is found to Interferon-c-induced neuronal differentiation of cord blood progenitors H Arien-Zakay et al induce apoptosis and sensitize neuroblastoma cells to chemotherapy, representing an attractive therapeutic agent. 31, 32 Neuroblastoma cells respond to IFN-g treatment by induction of 2 0 -5 0 -oligoadenylate synthetase, 33 upregulation of integrins 34, 35 and differential modulation of gene expression, 31, 36 in relation to neuronal differentiation.
In this study, we clearly showed that the clone SH-SY5Y human neuroblastoma release IFN-g to the culture medium, assumed to be partially involved in CM-induced HUCBNP neuronal differentiation. This conclusion is on the basis of several findings: (i) the positive immunoreactivity of the CM media to anti-human specific IFN-g antibody, (ii) the neutralization effect of anti-IFN-g antibody on CM-induced HUCBNP neuronal differentiation, (iii) the ability of CM to modulate typical IFN-related genes and furthermore (iv) treatment of HUCBNP with hrIFN-g resulted in an inhibition of proliferation and induction of neuronal differentiation. These novel findings shed light on the importance of IFN-g in the differentiation process of HUCBNP.
During the nervous system development, IFN-g plays an important role: IFN-g is expressed by human forebrain cells at early developmental stages, suggested to play a differentiating role in brain development 37 and it has been shown to promote differentiation of embryonic cortical and hypocampal 16 and septal 38 neurons, as well as neuronal progenitors. 17, 28 In this 
Figure 7
The cooperative effect between human recombinant IFN-g (hrIFN-g) and nerve growth factor (NGF) for induction of HUCBNP neuronal differentiation. HUCBNP were treated for either 7 (white bars) or 14 (black bars) days with 1 ng/ml hrIFN-g, 10 ng/ml NGF or a combination of both or left untreated. The differentiation expressed by neurites elongation (E) was measured as described in Materials and methods. * vs untreated Po0.01; ** vs treatment with individual factor Po0.01. HUCBNP, HUCB-derived neuronal progenitors. 40 and activation of ERK1/2 pathway, 27 a major essential pathway for induction of neurite outgrowths. 41 Other immunologically derived cytokines, such as interleukin-1 and interleukin-6 have also been shown to induce neurite outgrowths in neurons in vitro 42 and in vivo. 43 Furthermore, HUCB-derived progenitors secrete large amounts of these interleukins as well as angiogenic and neurotrophic factors, 44 which in an autocrine manner may be responsible for the neurite outgrowths and maintenance of the differentiated phenotype.
Although a lot of recent knowledge has been gained in the understanding of neuronal differentiation of HUCB-derived progenitors, 7, 45, 46 the molecular mechanisms underlying lineage origin and commitment toward neuronal phenotypes are just beginning to be addressed. 47 The HUCBNP cell population characterized in this study resembles in certain features the earlier reported unrestricted somatic stem cells isolated from cord blood. 46 The microarray gene expression analysis of HUCBNP indicates that the cells are negative for the hematopoietic markers CD34, CD49c, CD49d, CD62e, CD62p, CD106, CD117, CD133 (as also verified by immunophenotyping), CD235a , HLA-DRB4, HLA-DRB4 and HAS1, and positive for the mesenchymal markers CD13, CD29, CD44, CD49a/b (verified by Western), 6 CD49e, CD73, CD105 and vimentin. Those findings suggest a mesenchymal relation of HUCBNP, similar to the pluripotent unrestricted somatic stem cells cell population, 46 a possibility that deserves further investigation. An interesting difference between the present HUCBNP and unrestricted somatic stem cell progenitors is related to the expression of integrins. Whereas HUCBNP were selected by adherence and induction of differentiation on collagen, resulting in high expression of collagen-receptor integrins a 1 and a 2 (CD49a and CD49b), the unrestricted somatic stem cells were induced to differentiate on adherence to poly D-lysine/laminin, therefore resulting in a higher expression of the laminin receptor a 6 (CD49f). Furthermore, the differences in the differentiation protocols of neuronal progenitors from umbilical cord blood, probably generate variability in differentiation phenotypes and markers expression, 7, 9, 45, 46 as evident from the downregulation of hematopoietic-related genes in HUCBNP differentiated for 7 days on a collagen extracellular matrix protein ( Table 2 ). The present evidence that IFN-g may play an important role in certain steps of neuronal progenitors differentiation, contributes an additional complexity in HUCBNP neuronal commitment that deserves further clarification.
HUCB has established itself as a legitimate source for hematopoietic stem cell transplantations in the treatment of hematological disorders. 48 Besides this clinical use, neurological disorders such as trauma, stroke and neurodegenerative diseases, may represent another challenge for cell-based regenerative medicine using HUCB and derived progenitors. Studies by a number of groups support the idea that infusion of HUCB in animal models ameliorate central nervous system damage induced by hemorrhagic brain injury, 49 heatstroke, 50 middle cerebral artery occlusion, 51 traumatic brain injury 52 and laminectomy spinal cord injury. 53 In the injured brain a variety of cytokines including IFN-g 54 as well as neurotrophins such as NGF, 55 were found to be released by glial cells and infiltrating hematopoietic inflammatory cells. In this inflammatory environment, HUCB and derived neuronal progenitors may encounter a gradient of IFN-g and NGF on transplantation, and may respond by commitment to differentiation as presently found in vitro, providing a regenerative and/or neuroprotective effect. The present HUCBNP cells, both undifferentiated and differentiated, were recently found by our group to confer neuroprotection to neurons found under ischemic insults. 9 It is interesting to note that the mechanism of neuroprotectin was related to production of anti-oxidants and release of NGF, bFGF and VEGF. 9 Neurochemical and electrophysiological properties of HUCBNP are presently under investigation in our laboratory. Future experiments of HUCBNP implantation in damaged brain areas in animal models will uncover their neuroprotective mechanism, either by a bystander effect as found in vitro 9 or by reconstitution of neuronal pathways.
In summary, we found that IFN-g is present in the neuronal conditioning medium inducing neuronal differentiation of HUCB-derived progenitors. Furthermore, we showed that IFN-g promotes HUCBNP neuronal differentiation and facilitates the NGF-induced differentiation. This combination strategy may be considered in clinical relevant protocols for neuronal differentiation of progenitors from a hematopoietic origin.
